1. Introduction {#sec1-jcm-09-00167}
===============

Atrial fibrillation (AF) and chronic kidney disease (CKD) are common cardiac conditions that often coexist and predispose to each other \[[@B1-jcm-09-00167],[@B2-jcm-09-00167]\]. Since 2007, Japan has been a super-aging society, and accordingly, the incidence of AF is increasing. The expected number of AF patients will be over one million by 2030 in Japan \[[@B3-jcm-09-00167]\]. A prior study showed that approximately 65% of AF patients were shown to have mild-to-severe CKD (estimated glomerular filtration rate (eGFR) \< 80 mL/min/1.73 m^2^) \[[@B4-jcm-09-00167]\]. For stroke prevention in AF patients, we generally recommend anticoagulation therapy, which is with direct oral anticoagulants (DOACs) or vitamin K antagonists (e.g., warfarin). There are four DOACs including dabigatran, rivaroxaban, apixaban, and edoxaban, and large randomized controlled trials (RCTs) have shown the non-inferiority or superiority of DOACs compared to warfarin in the light of the safety and efficacy \[[@B5-jcm-09-00167],[@B6-jcm-09-00167],[@B7-jcm-09-00167],[@B8-jcm-09-00167]\]. Due to the convenience of DOACs over warfarin, such as the needlessness of anticoagulation monitoring and less food interactions, DOACs are widely used in clinical settings instead of the conventional anticoagulant treatment, warfarin. Huiart et al. reported that 61% of AF patients initially used one of the four DOACs as their anticoagulation therapy \[[@B9-jcm-09-00167]\].

AF and CKD are widely known as risk factors for adverse clinical events (e.g., strokes, major bleeding, and death). The substudy of the ATRIA study showed that AF patients with renal dysfunction had a higher rate of thromboembolisms than those with normal renal function \[[@B10-jcm-09-00167]\]. When we focused on Japanese cohort studies, the analyses related to renal function were performed in the J-RHYTHM Registry \[[@B11-jcm-09-00167]\] and Fushimi AF Registry \[[@B12-jcm-09-00167]\]. Those registries also showed that AF patients with renal impairment were associated with adverse clinical events, however, the rates of DOAC use were none or less than 10% because those registries were performed before or soon after DOACs became approved in Japan. In the Japanese AF patients stratified by the baseline renal function, the safety and effectiveness of DOACs as compared to warfarin were not evaluated in a Japanese registry.

By using the data from the SAKURA AF registry, a Japanese multicenter observational registry that included 3267 AF patients and over 50% being DOAC users (median follow-up period: 39 months), the present study was undertaken to analyze the clinical outcomes between the patients with and without renal dysfunction at baseline, and those between the patients taking DOACs and warfarin at each renal function level.

2. Methods {#sec2-jcm-09-00167}
==========

2.1. Study Design {#sec2dot1-jcm-09-00167}
-----------------

Our investigation was conducted as a sub-study of the SAKURA AF Registry (UMIN000014420) \[[@B13-jcm-09-00167],[@B14-jcm-09-00167]\], which was set up to support multicenter, prospective observational research by tracking clinical events in patients with AF for at least 2 years and up to 4 years after their enrollment in the registry. A total of 3267 patients were enrolled from 63 institutions (2 cardiovascular centers, 20 affiliated hospitals or community hospitals, and 41 private clinics) in the Tokyo area between September 2013 and December 2015 (Acknowledgments). The patients were eligible for inclusion if they were ≥20 years old, had been diagnosed as having non-valvular AF, and were being initiated/had already been initiated on oral anticoagulant therapy for stroke prevention. All the patients provided written informed consent for inclusion in the Registry.

2.2. Data Correction and Outcome Measures {#sec2dot2-jcm-09-00167}
-----------------------------------------

The patient data for the Registry were collected by means of a website and web-based registration system created for the Registry, through which, relevant clinical data such as the body height, body weight, type of AF (paroxysmal or non-paroxysmal AF), medical history, and laboratory data, including the prothrombin time-international normalized ratio (PT-INR) in warfarin users, and the serum creatinine (SCr) concentration, were collected. Follow-up information including those laboratory data were entered twice a year. Paroxysmal AF was defined as AF lasting for up to 7 days. A history of heart failure was defined as a diagnosis of heart failure prior to enrollment of the patient in the Registry. New use of an oral anticoagulant (OAC), defined as an OAC therapy initiated within 3 months before the patient's enrollment, was noted. The time in a therapeutic range (TTR) was calculated by the Rosendaal method \[[@B15-jcm-09-00167]\]. We calculated the TTR assuming a PT-INR of 1.6--2.6 for those aged ≥70 years and a PT-INR of 2.0--3.0 for those aged \<70 years, according to the 2013 Japanese Circulation Society guidelines \[[@B16-jcm-09-00167]\]. Good PT-INR control was defined arbitrarily as a TTR ≥65%. The creatinine clearance (CrCl) was estimated by the Cockcroft--Gault formula \[[@B17-jcm-09-00167]\]: CrCl (mL/min) = (140 − age (years)) × (weight (kg))/(72 × SCr (mg/dL)) × 0.85 (if female). For the purpose of this study, we defined a normal renal function as a CrCl greater than or equal to 80 mL/min, mild CKD as a CrCl between 50 and 80 mL/min, and moderate-to-severe CKD as a CrCl less than 50 mL/min. This cutoff value for the renal function was used in previous large trial analyses \[[@B18-jcm-09-00167],[@B19-jcm-09-00167]\]. We also recorded the incidences of death from any cause, cardiovascular events, strokes (ischemic strokes, hemorrhagic strokes, or transient ischemic attacks (TIAs))/systemic embolisms (SEs), and major bleeding. Cardiovascular (CV) events included the following events; heart failure requiring hospital admission, myocardial infarction, unstable angina, other cardiovascular events requiring hospital admission, and cardiac death. Strokes/SEs were excluded from the CV events. Major bleeding was defined as a reduction in the blood hemoglobin concentration by at least 2 g/dL, the need for a blood transfusion of at least 2 units of blood, and/or symptomatic bleeding in any critical area or organ. An analysis of the data from the Registry was conducted with the approval of the Nihon University School of Medicine Itabashi Hospital institutional review board and the review boards of the hospitals at which the patients were receiving treatment.

2.3. Statistical Analysis {#sec2dot3-jcm-09-00167}
-------------------------

The categorical variables are shown as numbers and percentages and continuous variables as the mean ± standard deviation or median values (25th, 75th percentiles), as appropriate. Differences in the categorical variables among the renal function groups were analyzed by a Fisher's exact test, while those for the continuous variables were analyzed by an analysis of variance or Kruskal--Wallis test, as appropriate. The trend tests were performed by using the Cochran--Armitage trend test for categorical variables and Jonckheere--Terpstra trend test for continuous variables. Kaplan--Meier curves were drawn for the time-to-events, which were compared by the log-rank test. To examine the associations between the renal dysfunction levels and development of adverse clinical events, we divided the subjects into 3 groups using the CrCl values; normal renal function (CrCl ≥ 80 mL/min), mild CKD (CrCl 50--79 mL/min), and moderate-severe CKD (CrCl \< 50 mL/min). A Cox proportional hazards model was used to assess the associations of the renal function levels with the risk of adverse clinical events, and the results are shown in terms of the hazard ratios (HRs) and 95% confidence intervals (CIs). For the multivariable analysis, we used the following factors as explanatory variables: the components of the CHADS~2~ score (congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, and a prior stroke or TIA) \[[@B20-jcm-09-00167]\], sex category, body weight (\<50 kg), type of AF, history of AF ablation, DOAC use, and antiplatelet drug use. The values of the age, body weight, and CrCl were also introduced into the model as continuous variables. In this case, the CrCl values were not normally distributed, and therefore, the log CrCl was used for the model. In the Cox model, we also assessed the consistency of the treatment effects by testing for any interactions between the treatment strategy (DOAC vs. warfarin) and renal function groups. All statistical analyses were performed with the JMP 14.1.0 (SAS Institute Inc., Cary, NC, USA) or EZR software (Saitama Medical Center, Jichi Medical University, Saitama, Japan), which is a graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Austria) \[[@B21-jcm-09-00167]\]. A two-sided *p* value of \<0.05 was considered as being indicative of statistical significance.

3. Results {#sec3-jcm-09-00167}
==========

3.1. Baseline Characteristics {#sec3dot1-jcm-09-00167}
-----------------------------

Because of the lack of SCr data, the baseline CrCl could be estimated in 3242 out of the total 3267 enrollees enrolled in this study. Of the 3242 total patients, 1679 (51.8%) were DOAC users and 1563 (48.2%) warfarin users. The median CrCl was 64.65 (IQR 50.16--82.03) mL/min. The number of patients in each group was 893 in the normal renal function group, 1550 in the mild CKD group, and 799 in the moderate-to-severe CKD group. Of those patients, the one-year follow-up information was entered for 3157 patients (97.4%) and two-year follow-up data for 2952 (91.1%). The baseline characteristics of the overall subject population and of each of the CrCl groups are shown in [Table 1](#jcm-09-00167-t001){ref-type="table"}. Compared to the patients with a CrCl ≥ 80 mL/min, the patients with a CrCl \< 50 mL/min were older, more frequently were female, had a lower body weight, were more likely to have non-paroxysmal AF, and to have higher CHADS~2~ and CHA~2~DS~2~-VASc scores. The prevalence of hypertension and diabetes did not significantly differ between the three groups.

3.2. Clinical Outcomes {#sec3dot2-jcm-09-00167}
----------------------

The median follow-up period was 39.4 (IQR 28.7--43.6) months, and the total person-years of this cohort was 9606. During the follow-up period, 198 patients (2.1 per 100 person-years) died; CV events occurred in 264 patients (2.8 per 100 person-years); strokes/SEs occurred in 131 patients (1.4 per 100 person-years); and major bleeding occurred in 123 patients (1.3 per 100 person-years). CV events were attributed to heart failure (*n* = 144 (54.5%)), cardiac death (*n* = 46 (17.4%)), myocardial infarctions and unstable angina (*n* = 21 (8.0%)), and other cardiovascular events (*n* = 53 (20.1%)). Kaplan--Meier curves for these adverse clinical events were drawn for each of the CrCl groups and are shown in [Figure 1](#jcm-09-00167-f001){ref-type="fig"}.

The patients with a low CrCl at the time of enrollment had a low event-free survival rate for all adverse clinical events in this study. The results of the Cox proportional hazard analysis related to the renal function are shown in [Table 2](#jcm-09-00167-t002){ref-type="table"}.

The risk of death was shown to be significantly higher for patients with a CrCl \< 50 mL/min than in those with a CrCl ≥ 80 mL/min (adjusted HR 2.40, 95% CI 1.41--4.07; *p* \< 0.0001), as was the risk of CV events (adjusted HR 2.53, 95% CI 1.62--3.94; *p* \< 0.0001), stroke/SE events (adjusted HR 2.13, 95% CI 1.34--4.00; *p* = 0.0182), and major bleeding events (adjusted HR 1.83, 95% CI 1.02--3.29; *p* = 0.0434). The results of the multivariable analysis of all factors used for the adjustment are shown in the [Table S1](#app1-jcm-09-00167){ref-type="app"}. Besides the impaired renal function, the age (≥75 years) (adjusted HR 2.59, 95% CI 1.78--3.75; *p* \< 0.0001) and a female sex (adjusted HR 0.57, 95% CI 0.39--0.84; *p* = 0.0038) were significantly associated with death, the age (≥75 years) (adjusted HR 1.45, 95% CI 1.09--1.93; *p* = 0.0117), paroxysmal AF (adjusted HR 1.35, 95% CI 1.03--1.76; *p* = 0.0269), history of heart failure (adjusted HR 2.10, 95% CI 1.62--2.74; *p* \< 0.0001), and antiplatelet use (adjusted HR 1.78, 95% CI 1.35--2.36; *p* \< 0.0001) were associated with CV events, and a history of a stroke/TIA (adjusted HR 2.17, 95% CI 1.44--3.27; *p* = 0.0002) was correlated with a stroke/SE. Only an impaired renal function was significantly associated with major bleeding ([Table S1](#app1-jcm-09-00167){ref-type="app"}). When assessing the continuous variables, the log CrCl was associated with death (adjusted HR 0.49, 95% CI 0.31--0.76; *p* = 0.0017), CV events (adjusted HR 0.41, 95% CI 0.29--0.58; *p* \< 0.0001), stroke/SE events (adjusted HR 0.50, 95% CI 0.28--0.88; *p* = 0.0171), and major bleeding events (adjusted HR 0.43, 95% CI 0.25--0.75; *p* = 0.0029). The results of this analysis of all factors are shown in [Table S2](#app1-jcm-09-00167){ref-type="app"}.

Using a Cox proportional hazard analysis, in each renal function level, the risk of all adverse events did not significantly differ between the DOAC and warfarin users ([Table 3](#jcm-09-00167-t003){ref-type="table"}).

The results of the incident number (parson-year) for each adverse clinical event in each CrCl group are shown in [Figure 2](#jcm-09-00167-f002){ref-type="fig"}. In the group of patients with a CrCl ≥ 80 mL/min, each adverse clinical event rate was shown to be almost equal (0.75--1.46 per 100 person-years). By a worsening renal function, the incidence of each adverse event increased, and especially, increasing rates of death and CV events were high. In the group of patients with a CrCl \< 50 mL/min, the clinical event rates were as follows: 4.86, 5.30, 2.32, and 2.14 per 100 person-years, for deaths, CV events, strokes/SEs, and major bleeding, respectively.

4. Discussion {#sec4-jcm-09-00167}
=============

There were three major findings of this study: (1) patients with moderate-severe CKD had a higher rate of all adverse clinical events including strokes/SEs, major bleeding, CV events, and death, as compared to those with a normal renal function. These results remained even after an adjustment by a multivariable analysis, (2) the use of DOACs (vs. warfarin) was not associated with a risk reduction of adverse clinical events, and (3) all adverse clinical event rates increased with a worsening renal function. The increased gradient of the death and CV event rates was predominant as compared to that of strokes/SEs and major bleeding.

The SAKURA AF Registry is a large-scale registry designed to collect data that can be used for a prospective evaluation of the outcomes among AF patients in Japan who are treated with DOACs or warfarin, and eventually, the usage of each OAC were found to be equal (51.8% for DOACs use and 48.2% for warfarin use). Since 2011, DOACs have been approved in Japan, and their prescription has been increasing because of the safety and convenience of DOACs compared to warfarin. In the SAKURA AF registry, DOAC users increased from 51.8% at baseline to 54.9% at two-years of follow-up \[[@B14-jcm-09-00167]\]. Because the previous Japanese registries were performed previous to the present study, the usage of DOACs in the previous registries was much lower than that in the present study (none for the J-RHYTHM Registry \[[@B22-jcm-09-00167]\], and 7.2% for the FUSHIMI AF Registry \[[@B23-jcm-09-00167]\]). We think, therefore, that the present registry is a better reflection of the current status of AF treatment in Japan, but the clinical use of DOACs are dramatically increasing now. The prevalence of each baseline renal function level in our registry was 27.5% for a CrCl ≥ 80 mL/min, 47.8% for a CrCl 50--79 mL/min, and 24.6% for a CrCl \< 50 mL/min. That was quite similar to the J-RHYTHM Registry, which used the Cockcroft-Gault formula to calculate the CrCl (29.9% for a CrCl ≥ 80 mL/min, 44.3% for a CrCl 50--79 mL/min, and 25.7% for a CrCl \< 50 mL/min) \[[@B11-jcm-09-00167]\]. One of the major findings of our registry was that patients with a CrCl of \< 50 mL/min had high HRs for all adverse events than did those with a normal renal function and its significance remained after a multivariable analysis (adjusted HR (95% CI): 2.40 (1.41--4.07) for death, 2.53 (1.62--3.94) for CV events, 2.13 (1.34--4.00) for strokes/SEs, and 1.83 (1.02--3.29) for major bleeding). To stratify the AF patients in terms of the risk of thromboembolisms or major bleeding, we often check the CHADS~2~ score or HAS-BLED score \[[@B20-jcm-09-00167],[@B24-jcm-09-00167]\]. In the present study, a multivariable analysis showed that only an impaired renal function was significantly associated with all adverse events, and the relative risk of all events was almost the highest among the other variables such as the age or comorbidities ([Table S1](#app1-jcm-09-00167){ref-type="app"}). Those results were also consistent when the CrCl values were assessed as continuous values. Therefore, an impaired renal function (CrCl \< 50 mL/min) would simply and accurately predict the adverse events in AF patients taking an OAC therapy. Compared to the other Japanese registry, the results of the adjusted HR for major bleeding events differed from that of the J-RHYTHM Registry \[[@B11-jcm-09-00167]\], in which the adjusted HRs (95% CI) for major hemorrhage events were not significant, 1.10 (0.58--2.09) for a CrCl 30--50 mL/min, and 1.37 (0.62--3.03) for a CrCl \< 30 mL/min (vs. CrCl ≥ 80 mL/min). In the Fushimi AF Registry, the adjusted HR for major bleeding was 2.08 (1.23--3.39) for a CrCl \< 30 mL/min (vs. CrCl ≥ 50 mL/min). The reason for this difference may be the difference in the patient's characteristics, status of the anticoagulated therapy, and definition of major bleeding events (major hemorrhage requiring hospital admission in the J-RHYTHM Registry \[[@B25-jcm-09-00167]\], and the same definition in the present study and Fushimi AF Registry \[[@B12-jcm-09-00167]\]).

In the present study, we analyzed the safety and effectiveness of DOACs as compared to warfarin in each renal function group, and those were statistically even between the DOACs and warfarin ([Table 3](#jcm-09-00167-t003){ref-type="table"}). In a previous subanalysis of the RCTs regarding renal function, the safety and efficacy of DOACs (vs. warfarin) were statistically shown. For major bleeding events, a low adjusted HR of apixaban compared to warfarin was shown in patients with a CrCl \< 50 mL/min (HR; 0.50, 95% CI; 0.38--0.66) \[[@B18-jcm-09-00167]\] and for that of edoxaban in patients with a CrCl \< 50 mL/min (HR; 0.76, 95% CI; 0.58--0.98) \[[@B26-jcm-09-00167]\]. For stroke/SE events, a low adjusted HR of dabigatran compared to warfarin was shown in patients with a CrCl \< 50 mL/min (HR; 0.56, 95% CI; 0.37--0.85) and for that of patients with a CrCl 50--79 mL/min (HR; 0.68, 95% CI; 0.50--0.92) \[[@B19-jcm-09-00167]\]. Compared to the present study, those RCTs included high risk patients with a CHADS~2~ score of more than 1--2 points and a high rate of antiplatelet therapy (29%--40%) \[[@B5-jcm-09-00167],[@B6-jcm-09-00167],[@B7-jcm-09-00167],[@B8-jcm-09-00167]\]. In addition, the median TTR of the present study was 71.5%, and 95% of warfarin users had already begun warfarin therapy for over 3 months at the time of enrollment \[[@B14-jcm-09-00167]\]. These patient background differences, and stability of the warfarin therapy may have attributed to the equality of the clinical outcomes between DOACs and warfarin in the present Japanese real-world registry. This finding supports that warfarin users with a stable PT-INR control could safely and effectively continue warfarin therapy as compared to DOACs, regardless of having concomitant CKD.

The incidence rates of each adverse event increased with a worsening renal function at baseline ([Figure 2](#jcm-09-00167-f002){ref-type="fig"}). The incidence rates of each adverse event were equal in the patients with a normal renal function, and furthermore, those of death and CV events were more than two-fold compared to those for strokes/SEs and major bleeding in the patient group with a CrCl \< 50 mL/min. In the large RCTs comparing DOACs versus warfarin, the all-cause mortality was 2.04%--2.71%/year in patients with a normal renal function, 3.15%--3.56%/year in patients with mild CKD, and 6.28%--8.30%/year in patients with moderate-severe CKD. The annual stroke/SE rate was 0.81%--1.12%/year in patients with a normal renal function, 1.21%--1.69%/year in patients with mild CKD, and 1.21%--2.67%/year in patients with moderate-severe CKD. The incidence rate of major bleeding was 1.25%--1.84%/year in patients with a normal renal function, 2.45%--3.21%/year in patients with mild CKD, and 3.21%--6.44%/year in patients with moderate--severe CKD \[[@B18-jcm-09-00167],[@B19-jcm-09-00167]\]. In the prospective GARFIELD-AF Registry including 35 countries and over 33,000 patients, the events rates per 100 person-years stratified by the renal function were as follows: deaths: 3.22 for a normal renal function, 5.60 for mild CKD, and 10.35 for moderate-severe CKD; strokes/SEs: 1.03 for a normal renal function, 1.21 for mild CKD, and 2.25 for moderate-severe CKD; and major bleeding: 0.63 for a normal renal function, 0.98 for mild CKD, and 1.85 for moderate-severe CKD) \[[@B27-jcm-09-00167]\]. Although the adverse event rates in the present Japanese study were lower than those in the previous worldwide data, the tendency of the event rates in each renal function group was similar to the present study. This finding suggested that when examining AF patients, we should understand that the characteristics of possible adverse events vary with the status of the renal function, and patients with AF and an impaired renal function should be more aware of deaths and CV events as well as strokes/SEs and major bleeding.

Our study results should be interpreted in light of the study limitations. First, the study was conducted as a retrospective analysis of prospectively collected data. Some findings were not consistent with those of prior RCTs, however, we believe that the present real-world registry data reflects the current status of AF treatment in Japan, and has a clinical implication for the clinical management of AF patients receiving OACs. Second, we were not able to collect the renal function data for all participants by using the Cockcroft--Gault formula. Third, in the present study, the number of users of each of the four DOACs was not sufficient to allow for a multivariate outcome analysis. Finally, only selected institutions within a limited geographical area in Japan participated in the SAKURA AF Registry, and it would be difficult to assume that our findings can be generalized to the entire population of AF patients in Japan. It should be noted, however, that patient selection and regional enrollment biases are limitations of all prospective observational studies.

5. Conclusions {#sec5-jcm-09-00167}
==============

Patients with moderate-severe CKD had a high risk for death, CV events, strokes/SEs, and major bleeding. For each renal function level, a superiority of DOACs over warfarin regarding the clinical outcomes was not found. We should understand that the trend in the adverse clinical outcomes in AF patients seems to differ according to the baseline renal function level.
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###### 

Patient characteristics according to the renal function.

  Number of Patients (%)                      Overall                Normal Renal Function (CrCl ≥ 80 mL/min)   Mild CKD (CrCl 50--79 mL/min)   Moderate--Severe CKD (CrCl \< 50 mL/min)   *p*-Value \*   *p*-Value for Trend
  ------------------------------------------- ---------------------- ------------------------------------------ ------------------------------- ------------------------------------------ -------------- ---------------------
  Age (years)                                 72.00 ± 9.38           63.54 ± 8.70                               72.82 ± 6.61                    79.87 ± 6.69                               \<0.001        \<0.001
  \<65                                        614 (18.9)             443 (49.6)                                 159 (10.3)                      12 (1.5)                                   \<0.001        \<0.001
  65--74                                      1286 (39.7)            376 (42.1)                                 759 (49.0)                      151 (18.9)                                                
  ≥75                                         1342 (41.4)            74 (8.3)                                   632 (40.8)                      636 (79.6)                                                
  Female sex                                  848 (26.2)             115 (12.9)                                 410 (26.5)                      323 (40.4)                                 \<0.001        \<0.001
  Body height (cm)                            162.48 ± 9.49          168.01 ± 7.96                              162.31 ± 8.41                   156.62 ± 9.44                              \<0.001        \<0.001
  Body weight (kg)                            63.85 ± 12.96          74.16 ± 12.47                              62.67 ± 10.09                   54.61 ± 10.17                              \<0.001        \<0.001
  BMI (kg/m^2^)                               24.05 ± 3.73           26.25 ± 4.01                               23.74 ± 3.16                    22.19 ± 3.19                               \<0.001        \<0.001
  Paroxysmal AF                               1195 (36.9)            351 (39.3)                                 593 (38.3)                      251 (31.4)                                 0.001          0.001
  Medical history                                                                                                                                                                                         
  Hypertension                                2312 (71.3)            616 (69.0)                                 1106 (71.4)                     590 (73.8)                                 0.087          0.027
  Dyslipidemia                                1256 (38.7)            371 (41.5)                                 635 (41.0)                      250 (31.3)                                 \<0.001        \<0.001
  Diabetes                                    741 (22.9)             221 (24.7)                                 338 (21.8)                      182 (22.8)                                 0.249          0.310
  Heart failure                               719 (22.2)             165 (18.5)                                 292 (18.8)                      262 (32.8)                                 \<0.001        \<0.001
  Stroke/TIA                                  364 (11.2)             54 (6.0)                                   193 (12.5)                      117 (14.6)                                 \<0.001        \<0.001
  Ischemic heart disease                      312 (9.6)              57 (6.4)                                   159 (10.3)                      96 (12.0)                                  \<0.001        \<0.001
  AF ablation                                 299 (9.2)              147 (16.5)                                 123 (7.9)                       29 (3.6)                                   \<0.001        \<0.001
  DOAC use                                    1679 (51.8)            493 (55.2)                                 818 (52.8)                      368 (46.1)                                 \<0.001        \<0.001
  Warfarin use                                1563 (48.2)            400 (44.8)                                 732 (47.2)                      431 (53.9)                                 \<0.001        \<0.001
  TTR (%)                                     71.50 (43.20, 93.40)   64.60 (33.80, 87.67)                       74.60 (46.18, 94.30)            74.20 (49.70, 94.90)                       \<0.001        \<0.001
  TTR ≥ 65%                                   805 (57.6)             176 (49.7)                                 394 (60.1)                      235 (60.7)                                 0.002          0.003
  Antiplatelet use                            517 (15.9)             92 (10.3)                                  248 (16.0)                      177 (22.2)                                 \<0.001        \<0.001
  Antiarrhythmic drug class Ⅰ                 423 (13.0)             141 (15.8)                                 196 (12.6)                      86 (10.8)                                  0.007          0.002
  Beta-blocker use                            1471 (45.4)            403 (45.1)                                 689 (44.5)                      379 (47.4)                                 0.382          0.362
  Amiodarone use                              32 (1.0)               9 (1.0)                                    11 (0.7)                        12 (1.5)                                   0.184          0.334
  Bepridil use                                322 (9.9)              113 (12.7)                                 168 (10.8)                      41 (5.1)                                   \<0.001        \<0.001
  CHADS~2~ score                              2 (1, 2)               1 (1, 2)                                   2 (1, 2)                        2 (2, 3)                                   \<0.001        \<0.001
  CHA~2~DS~2~-VASc score                      3 (2, 4)               2 (1, 3)                                   3 (2, 4)                        4 (3, 5)                                   \<0.001        \<0.001
  New use (OAC therapy duration \<3 months)   637 (19.6)             186 (20.8)                                 301 (19.4)                      150 (18.8)                                 0.541          0.283
  SCr (mg/dL)                                 0.87 (0.75, 1.04)      0.78 (0.69, 0.86)                          0.88 (0.75, 1.00)               1.09 (0.88, 1.34)                          \<0.001        \<0.001
  CrCl (mL/min)                               64.65 (50.16, 82.03)   94.26 (86.11, 108.90)                      63.74 (57.01, 70.88)            40.05 (32.57, 45.93)                       \<0.001        \<0.001

Values are the mean ± SD, median (25th, 75th percentiles), or number (%) of patients. AF = atrial fibrillation; BMI = body mass index; CHADS~2~ = congestive heart failure, hypertension, age \> 75 years, diabetes mellitus, prior stroke or TIA (doubled); CHA~2~DS~2~-VASc, congestive heart failure, hypertension, age \>75 years (doubled), Diabetes mellitus, prior stroke, TIA, or thromboembolic event (doubled), vascular disease, age 65--74 years, sex category; CKD = chronic kidney disease; CrCl = creatinine clearance; DOAC = direct oral anticoagulant; OAC = oral anticoagulant; SCr = serum creatinine; TIA = transient ischemic attack; TTR = time therapeutic range. \* *p*-Value for comparison between renal function groups based on Fisher's exact test, analysis of variance, or Kruskal--Wallis test, as appropriate.
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###### 

Adverse clinical outcomes and results of the Cox proportional hazards model according to the renal function.

  Outcome           Number of Patients   Number of Events   Hazard Ratio                                       
  ----------------- -------------------- ------------------ ------------------- ---------- ------------------- ----------
  Death                                                                                                        
  ≥80 (reference)   893                  26                 1.00                           1.00                
  50--79            1550                 63                 1.41 (0.89--2.23)   0.138      0.99 (0.60--1.62)   0.9635
  \<50              799                  109                5.14 (3.35--7.89)   \<0.0001   2.40 (1.41--4.07)   0.0012
  CV events                                                                                                    
  ≥80 (reference)   893                  39                 1.00                           1.00                
  50--79            1550                 113                1.72 (1.19--2.47)   0.0036     1.51 (1.03--2.22)   0.0358
  \<50              799                  112                3.67 (2.55--5.28)   \<0.0001   2.53 (1.62--3.94)   \<0.0001
  Stroke/SE                                                                                                    
  ≥80 (reference)   893                  20                 1.00                           1.00                
  50--79            1550                 60                 1.77 (1.07--2.93)   0.0273     1.45 (0.84--2.47)   0.1787
  \<50              799                  51                 3.15 (1.88--5.28)   \<0.0001   2.13 (1.34--4.00)   0.0182
  Major bleeding                                                                                               
  ≥80 (reference)   893                  28                 1.00                           1.00                
  50--79            1550                 48                 1.00 (0.63--1.59)   0.9981     0.92 (0.56--1.51)   0.7389
  \<50              799                  47                 2.08 (1.30--3.33)   0.0021     1.83 (1.02--3.29)   0.0434

The Cox model was adjusted for the sex, age (≥75 years), lower body weight (\<50 kg), AF type, hypertension, diabetes, history of heart failure, history of a stroke/TIA, history of AF ablation, DOAC use, antiplatelet use. CI = confidence intervals; CrCl = creatinine clearance; CV = cardiovascular; SE = systemic embolism.
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###### 

Adjusted hazard ratio of the adverse clinical events of DOACs (versus warfarin) stratified by the renal function.

  Clinical Outcome        Normal Renal Function (CrCl ≥ 80 mL/min)   Mild CKD (CrCl 50--79 mL/min)   Moderate-Severe CKD (CrCl \< 50 mL/min)   *p*-Value for Interaction                                
  ----------------------- ------------------------------------------ ------------------------------- ----------------------------------------- --------------------------- ------------------- -------- --------
  Death                   0.97 (0.44--2.12)                          0.9112                          1.09 (0.66--1.81)                         0.7322                      0.99 (0.67--1.47)   0.9671   0.9369
  Cardiovascular events   1.26 (0.66--2.41)                          0.4889                          1.19 (0.81--1.73)                         0.3721                      1.02 (0.69--1.50)   0.9272   0.6535
  Stroke/SE               0.77 (0.31--1.89)                          0.5705                          1.43 (0.85--2.41)                         0.1774                      1.30 (0.74--2.27)   0.3664   0.4442
  Major bleeding          0.90 (0.42--1.91)                          0.7825                          0.98 (0.55--1.74)                         0.9443                      0.95 (0.53--1.73)   0.8775   0.9946

Adjusted for the sex, age (≥75 years), lower body weight (\<50 kg), AF type, hypertension, diabetes, history of heart failure, history of a stroke/TIA, history of AF ablation, antiplatelet use. CI = confidence intervals; CKD = chronic kidney disease; CrCl = creatinine clearance; HR = hazard ration; SE = systemic embolism. *p*-Value for interaction is for the interaction of treatment and renal function subgroups.

[^1]: Membership of the SAKURA AF Registry Investigators is provided in the Acknowledgments.
